← Issue №10/ week of Sep 6, 2026/IBD

Extraintestinal manifestations in Korean patients with inflammatory bowel disease: A nationwide population-based study from 2005 to 2017.

From GI Signals issue №10: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD retrospective · n=69,414 · Sep 1, 2026 · Inflamm Bowel Dis · IF 4.5

Extraintestinal manifestations in Korean patients with inflammatory bowel disease: A nationwide population-based study from 2005 to 2017.

Epidemiologyepidemiologyulcerative colitisCrohn's disease
Clinical takeawayCounsel IBD patients, especially women, smokers, those with low socioeconomic status, or higher comorbidity burden (Charlson Comorbidity Index score ≥1), about EIM risks and monitor for dermatologic, musculoskeletal, hepatopancreaticobiliary, and ophthalmologic symptoms, particularly in years 4-6 post-diagnosis, noting rising incidence over time.
What it found42.23% of Korean IBD patients developed at least one EIM, with dermatologic (17.02%), musculoskeletal (16.36%), hepatopancreaticobiliary (15.48%), and ophthalmologic (7.83%) manifestations most common; most EIMs emerged 4-6 years post-diagnosis.
ContextConfirms high EIM burden in East Asian IBD patients, aligning with Western data but providing specific incidence rates and timing for Korean populations, with novel risk factor associations (socioeconomic status, Charlson Comorbidity Index score).
Reinforcessuggested applicable standard· ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes)

Decision at stakemonitoring for extraintestinal manifestations in ulcerative colitis

Confirm ulcerative colitis with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step CDI testing. … Begin CRC surveillance 8-10 years after DIAGNOSIS for extensive or left-sided disease; isolated proctitis follows average-risk screening.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Confirm ulcerative colitis with endoscopy showing continuous colonic inflammation from the rectum plus histology, after excluding infection with two-step CDI testing. Treat mild-moderate disease with 5-ASA by route and extent (suppository for proctitis, enema for left-sided, oral plus rectal for extensive); if 5-ASA fails, treat as moderate-to-severe rather than stepping up gradually. Position advanced therapy by EFFICACY TIER, not by an anti-TNF-first rule. Advanced-therapy-naive, higher efficacy: infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab; intermediate: golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab; lower: adalimumab. PREVIOUSLY TNF-EXPOSED, higher efficacy: tofacitinib, upadacitinib, ustekinumab; lower: adalimumab, vedolizumab, ozanimod, etrasimod - S1P modulators are weakest in exactly this group. Do not cycle within the anti-TNF class after primary non-response; switch mechanism. Apply treat-to-target (STRIDE-II) to endoscopic improvement (MES 0-1). Screen for acute severe UC by Truelove-Witts and admit for IV steroids. Begin CRC surveillance 8-10 years after DIAGNOSIS for extensive or left-sided disease; isolated proctitis follows average-risk screening.

ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120(6):1187-1224; AGA Living Guideline on Pharmacological Management of Moderate-to-Severe UC, Gastroenterology 2024 (panel review March 2026, no changes) ↗
Park SS … Ahn BK · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №10 Every paper GI Signals surfaces gets a page like this one. All issues